JAK2 activation is the driver mechanism in negative myeloproliferative neoplasms (MPN), i. 13] Recent data have documented the existence of MF HSC residing in the spleen with increased transplantation capacity in ZM 336372 comparison to blood or marrow HSC [14]. Cues promoting this MF HSC circulation and homing to extramedullary territories have not been completely… Continue reading JAK2 activation is the driver mechanism in negative myeloproliferative neoplasms (MPN),